What is lutetium-177 used for?

Lutetium-177 is a radioactive form of the element lutetium. In treatment, it is linked to a carrier molecule designed to recognise a target found on certain tumour cells. After administration, the carrier helps bring the radioactive material close to those cells, where its radiation can damage them. It may also expose some nearby tissue, so the oncology and nuclear medicine teams plan treatment carefully.

This treatment is only suitable when the tumour has the relevant target and when your health, blood counts, kidney function, and other factors support its use. It is not the same as external radiation from a machine. Read about [Lutetium-177](/materials/lutetium-177/) and [Targeted Radioisotope Therapy](/treatments/radiation-oncology/targeted-radioisotope-therapy/).

Your team may arrange tests to confirm the target and check blood counts and organ function before treatment. Follow instructions about fluids, medicines, and contact precautions after administration. Tell the team if you could be pregnant, are breastfeeding, have kidney problems, or care for someone who needs close assistance. Keep the written aftercare instructions available at home and attend planned monitoring appointments.

Call your treatment team about persistent vomiting, inability to drink, fever, unusual bruising or bleeding, reduced urine, or severe abdominal pain. Follow the radiation-safety instructions supplied by your centre when asking for help. Seek urgent care for severe breathlessness, collapse, confusion, or uncontrolled bleeding, and tell the receiving team that you recently received radionuclide treatment.

Ask which tumour target is being treated, what tests confirm eligibility, how kidney and blood-cell monitoring will be arranged, and which contact precautions apply after treatment. Ask how symptoms should be reported and which medicines or supplements need review.